Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the safety of deoxycholic acid subcutaneous injections in the submental area (below the chin).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Deoxycholic Acid 2 mg/cm² | Experimental | Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Deoxycholic acid injection | Drug | Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | Serious AEs include any event that met one or more of the following criteria: was fatal or life-threatening, required inpatient hospitalization or prolonged a hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or a significant medical hazard. The severity of each AE was defined as either: Mild: The participant was aware of the sign or symptom, but it was easily tolerated. Moderate: The sign or symptom caused discomfort and interfered with usual activity. Severe: The sign or symptom was incapacitating, and the participant was unable to engage in usual activity. The investigator determined the relationship of each AE to the study drug using the question: "Is there a reasonable possibility that the event may have been caused by treatment with the study drug?" | Up to 12 months after last treatment (maximum of 18 months from first treatment) |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS) | The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). A negative change from baseline indicates improvement. | Baseline and months 3, 6, 9, and 12 after last treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frederick Beddingfield, III, M.D., PhD | Kythera Biopharmaceuticals, Inc | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mark Rubin | Beverly Hills | California | 90212 | United States | ||
| Mitchel Goldman |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31524342 | Derived | Beer K, Weinkle SH, Cox SE, Rubin MG, Shamban A, Somogyif C. ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat: Results From a 12-Month Open-Label Study. J Drugs Dermatol. 2019 Sep 1;18(9):870-877. |
Not provided
Not provided
Not provided
The study was conducted at 18 investigational centers in the United States.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Deoxycholic Acid 2 mg/cm² | Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Mean Change From Baseline in Patient-Reported Submental Fat Scale Rating Scale (PR-SMFRS) | The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat). A negative change from baseline indicates improvement. | Baseline and month 3 and month 12 after last treatment |
| Percentage of Participants Who Achieved a Composite 1-grade Response | A composite 1-grade response is defined as at least a 1-grade improvement from baseline on both the CR-SMFRS and PR-SMFRS. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat). | Baseline and month 3 and month 12 after last treatment |
| Percentage of Participants Who Achieved a Composite 2-grade Response | A composite 2-grade response is defined as at least a 2-grade improvement from baseline on both the CR-SMFRS and PR-SMFRS. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat). | Baseline and month 3 and month 12 after last treatment |
| Mean Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS) | The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) related to the appearance of submental fullness as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from baseline indicates improvement. | Baseline and month 3 and month 12 after last treatment |
| Mean Change From Baseline in Subject Self Rating Scale (SSRS) | The SSRS assesses participants' satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6 (0 = extremely dissatisfied, 1 = dissatisfied, 2 = slightly dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = slightly satisfied, 5 = satisfied and 6 = extremely satisfied). A positive change from baseline indicates improvement. | Baseline and month 3 and month 12 after last treatment |
| Mean Change From Baseline in Self-rating of Attractiveness | Self-rating of Attractiveness assesses aspects of appearance from the participant's perspective with a series of 6 questions: How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are?" Each question was answered on a scale from 1 to 9 (1 = not at all attractive, 5 = neither attractive nor unattractive, and 9 = extremely attractive). A positive change from baseline indicates improvement. | Baseline and month 3 and month 12 after last treatment |
| Response to Subject Global Questions | Participants answered 3 questions on a 7-point scale that ranged from "a great deal worse" to "a great deal better" (questions 1 and 2) or from "extremely dissatisfied" to "extremely satisfied" (question 3). Question 1: Since the start of the study, how would you rate the fat under your chin right now? Question 2: Since the start of the study, how would you rate the definition between your chin and neck right now? Question 3: How satisfied are you with the treatment you received in this study? | Month 3 and month 12 after last treatment |
| Percent Change From Baseline in Submental Fat Thickness | Submental fat thickness was measured using calipers. | Baseline and month 3 and month 12 after last treatment |
| Change From Baseline in Submental Skin Laxity Grade (SMSLG) | SMSLG assessment was based on clinical evaluation and palpation of the submental area. The SMSLG scale incorporates 3 features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Grade 1 (none): no or minimal superficial wrinkling, skin well apposed to deeper neck structures, no skin redundancy (no skin draping (vertical folds) or skin sagging (horizontal folds)); Grade 2 (mild): mild superficial wrinkling, skin well apposed to deeper neck structures, minimal skin redundancy (slight skin draping and sagging); Grade 3 (moderate): may have mild to moderate superficial wrinkling, skin has mild to moderate separation from deeper neck structures, moderate skin redundancy (moderate skin draping and skin sagging); Grade 4 (severe): mild to marked superficial wrinkling, loose skin separated from deeper neck structures, marked skin redundancy (marked skin draping and sagging). | Baseline and month 3 and month 12 after last treatment |
| Change From Baseline in Line Drawing Assessment | Each participant was given 2 example line drawings representing each of the 5 submental fat grades (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme) and asked to select the drawing that best represents their current profile. Improvement is any decrease in grade, and worsening is any increase in grade. | Baseline and month 3 after last treatment |
| La Jolla |
| California |
| 92121 |
| United States |
| Jeffrey Klein | San Juan Capistrano | California | 92675 | United States |
| Ava Shamban | Santa Monica | California | 90404 | United States |
| Steven Teitelbaum | Santa Monica | California | 90404 | United States |
| Susan Weinkle | Bradenton | Florida | 34209 | United States |
| Palm Beach Cosmetic | West Palm Beach | Florida | 33401 | United States |
| Steven Dayan | Chicago | Illinois | 60611 | United States |
| Lupo Center for Aesthetic and General Dermatology | New Orleans | Louisiana | 70124 | United States |
| Grekin Skin Institute | Warren | Michigan | 48088 | United States |
| David Goldberg, MD | Hillsborough | New Jersey | 08844 | United States |
| Roy Geronemus, MD | New York | New York | 10016 | United States |
| Macrene Alexiades-Armenakas | New York | New York | 10028 | United States |
| Sue Ellen Cox | Chapel Hill | North Carolina | 27517 | United States |
| Richard Fried | Yardley | Pennsylvania | 19067 | United States |
| Michael Gold | Nashville | Tennessee | 37215 | United States |
| Suzanne Bruce | Houston | Texas | 77056 | United States |
| Jeffrey Adelglass | Plano | Texas | 75093 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Deoxycholic Acid 2 mg/cm² | Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Age, Customized | Number | participants |
| |||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
| |||||||||||||||||||||||
| Weight | Mean | Standard Deviation | kg |
| ||||||||||||||||||||||
| Body Mass Index (BMI) | Mean | Standard Deviation | kg/m² |
| ||||||||||||||||||||||
| Fitzpatrick Skin Type | Fitzpatrick Skin Type is a numerical classification schema for human skin color and typical response to ultraviolet (UV) light:
| Number | participants |
| ||||||||||||||||||||||
| Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) Rating | CR-SMFRS Ratings:
| Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Adverse Events (AEs) | Serious AEs include any event that met one or more of the following criteria: was fatal or life-threatening, required inpatient hospitalization or prolonged a hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or a significant medical hazard. The severity of each AE was defined as either: Mild: The participant was aware of the sign or symptom, but it was easily tolerated. Moderate: The sign or symptom caused discomfort and interfered with usual activity. Severe: The sign or symptom was incapacitating, and the participant was unable to engage in usual activity. The investigator determined the relationship of each AE to the study drug using the question: "Is there a reasonable possibility that the event may have been caused by treatment with the study drug?" | Safety population | Posted | Number | participants | Up to 12 months after last treatment (maximum of 18 months from first treatment) |
|
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in Clinician-Reported Submental Fat Rating Scale Scores (CR-SMFRS) | The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). A negative change from baseline indicates improvement. | Treatment effect population (all participants who received at least 1 injection with study drug and had any posttreatment data for treatment effect variables or for the submental skin laxity grade) and with available data at each time point (indicated by "n"). | Posted | Mean | Standard Deviation | units on a scale | Baseline and months 3, 6, 9, and 12 after last treatment |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in Patient-Reported Submental Fat Scale Rating Scale (PR-SMFRS) | The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat). A negative change from baseline indicates improvement. | Treatment effect population with available data at baseline (163) and at each time point (indicated by "n") | Posted | Mean | Standard Deviation | units on a scale | Baseline and month 3 and month 12 after last treatment |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Achieved a Composite 1-grade Response | A composite 1-grade response is defined as at least a 1-grade improvement from baseline on both the CR-SMFRS and PR-SMFRS. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat). | Treatment effect population with available data at baseline and at each time point (indicated by "n") | Posted | Number | percentage of participants | Baseline and month 3 and month 12 after last treatment |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Achieved a Composite 2-grade Response | A composite 2-grade response is defined as at least a 2-grade improvement from baseline on both the CR-SMFRS and PR-SMFRS. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme). The PR-SMFRS is based on the participant's response to the question "How much fat do you have under your chin right now?" and answered on a 5-point ordinal scale (0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat). | Treatment effect population with available data at baseline and at each time point (indicated by "n") | Posted | Number | percentage of participants | Baseline and month 3 and month 12 after last treatment |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS) | The PR-SMFIS assesses the impact of submental fat on self-perception of 6 emotional and visual characteristics (unhappy, bothered, self-conscious, embarrassed, look older, and look overweight) related to the appearance of submental fullness as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10. Scores for the 6 items were averaged to generate a PR-SMFIS total scale score ranging from 0 to 10 where 0 is a positive outcome and 10 is a negative outcome. A negative change from baseline indicates improvement. | Treatment effect population with available data at baseline and each time point (indicated by "n") | Posted | Mean | Standard Deviation | units on a scale | Baseline and month 3 and month 12 after last treatment |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in Subject Self Rating Scale (SSRS) | The SSRS assesses participants' satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6 (0 = extremely dissatisfied, 1 = dissatisfied, 2 = slightly dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = slightly satisfied, 5 = satisfied and 6 = extremely satisfied). A positive change from baseline indicates improvement. | Treatment effect population with available data (indicated by "n") | Posted | Mean | Standard Deviation | units on a scale | Baseline and month 3 and month 12 after last treatment |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in Self-rating of Attractiveness | Self-rating of Attractiveness assesses aspects of appearance from the participant's perspective with a series of 6 questions: How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are?" Each question was answered on a scale from 1 to 9 (1 = not at all attractive, 5 = neither attractive nor unattractive, and 9 = extremely attractive). A positive change from baseline indicates improvement. | Treatment effect population with available data at baseline (163), month 3 (144), and month 12 (130) | Posted | Mean | Standard Deviation | units on a scale | Baseline and month 3 and month 12 after last treatment |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Response to Subject Global Questions | Participants answered 3 questions on a 7-point scale that ranged from "a great deal worse" to "a great deal better" (questions 1 and 2) or from "extremely dissatisfied" to "extremely satisfied" (question 3). Question 1: Since the start of the study, how would you rate the fat under your chin right now? Question 2: Since the start of the study, how would you rate the definition between your chin and neck right now? Question 3: How satisfied are you with the treatment you received in this study? | Treatment effect population with available data at each time point | Posted | Number | participants | Month 3 and month 12 after last treatment |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percent Change From Baseline in Submental Fat Thickness | Submental fat thickness was measured using calipers. | Treatment effect population with available data at baseline (164) and at each time point | Posted | Mean | Standard Deviation | percent change | Baseline and month 3 and month 12 after last treatment |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Submental Skin Laxity Grade (SMSLG) | SMSLG assessment was based on clinical evaluation and palpation of the submental area. The SMSLG scale incorporates 3 features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Grade 1 (none): no or minimal superficial wrinkling, skin well apposed to deeper neck structures, no skin redundancy (no skin draping (vertical folds) or skin sagging (horizontal folds)); Grade 2 (mild): mild superficial wrinkling, skin well apposed to deeper neck structures, minimal skin redundancy (slight skin draping and sagging); Grade 3 (moderate): may have mild to moderate superficial wrinkling, skin has mild to moderate separation from deeper neck structures, moderate skin redundancy (moderate skin draping and skin sagging); Grade 4 (severe): mild to marked superficial wrinkling, loose skin separated from deeper neck structures, marked skin redundancy (marked skin draping and sagging). | Treatment effect population with available data (indicated by "n") | Posted | Mean | Standard Deviation | units on a scale | Baseline and month 3 and month 12 after last treatment |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Line Drawing Assessment | Each participant was given 2 example line drawings representing each of the 5 submental fat grades (0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme) and asked to select the drawing that best represents their current profile. Improvement is any decrease in grade, and worsening is any increase in grade. | Treatment effect population with available data | Posted | Number | participants | Baseline and month 3 after last treatment |
|
|
Up to 12 months after last treatment (maximum of 18 months from first treatment)
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Deoxycholic Acid 2 mg/cm² | Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. | 7 | 165 | 160 | 165 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 14.1 | Systematic Assessment |
| |
| Thyroid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 14.1 | Systematic Assessment |
| |
| Cardiac death | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Diverticulitis | Infections and infestations | MedDRA 14.1 | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Cervical polyp | Reproductive system and breast disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Stent placement | Surgical and medical procedures | MedDRA 14.1 | Systematic Assessment |
| |
| Arteriosclerosis | Vascular disorders | MedDRA 14.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Injection site hematoma | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Injection site anesthesia | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Injection site pain | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Injection site edema | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Injection site erythema | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Injection site induration | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Injection site swelling | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Injection site pruritus | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Injection site nodule | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Injection site paresthesia | General disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 14.1 | Systematic Assessment |
| |
| Blood triglycerides increased | Investigations | MedDRA 14.1 | Systematic Assessment |
| |
| Blood glucose increased | Investigations | MedDRA 14.1 | Systematic Assessment |
|
The clinical study agreement requires that the investigator or institution obtain written consent from Kythera Biopharmaceuticals, Inc. prior to presenting and/or publishing results of this study.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Trial Disclosure | Kythera Biopharmaceuticals, Inc. | clinical_trials@kythera.com |
| ID | Term |
|---|---|
| D008224 | Lymphoma, Follicular |
| ID | Term |
|---|---|
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003840 | Deoxycholic Acid |
| ID | Term |
|---|---|
| D002793 | Cholic Acids |
| D001647 | Bile Acids and Salts |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D002757 | Cholanes |
Not provided
Not provided
| > 65 years |
|
| Black or African American |
|
| Multiple |
|
| Other |
|
| White |
|
|
| 4 |
|
| Title | Measurements |
|---|---|
|
| Adverse event leading to withdrawal from treatment |
|
| Adverse event leading to study discontinuation |
|
| Adverse event leading to death |
|
| Adverse event related to study drug |
|
| Serious adverse event related to study drug |
|
| Adverse event associated with the treatment area |
|
|
|
|
|
|
|
|
|
|
| Participants |
|
|
|